Farah Khorassani, PharmD.
Clinical Assistant Professor of Pharmacy Practice, St. John’s University, Queens, NY.
Dr. Khorassani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
VMAT-2 inhibitors significantly reduce the symptoms of tardive dyskinesia. We learn how to prescribe them and what side effects and drug interactions to watch for.
Chris Aiken, MD.
Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.
Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
The VMAT2 inhibitors are FDA approved for tardive dyskinesia (TD), but there are 8 off-label options to consider as well. See how they stack up here, and learn why the atypical antipsychotics ─ with one exception ─ have not put an end to this insidious side effect.